Flexion Therapeutics Inc (FLXN) 21.29 $FLXN
3 Stocks Spiking on Big Volume: Baidu, LogMeIn and Flexion
at The Street - Fri Feb 13, 12:26PM CST
Keep these stocks rising on unusual volume on your trading radar.
FLXN: 21.29 (+0.28), BIDU: 212.13 (+7.11), LOGM: 52.22 (+4.17)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Flexion Therapeutics begins Phase 3 clinical trial of FX006 for osteoarthritis of the knee
M2 - Tue Feb 03, 8:26PM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) said on Monday that it has dosed the first patient with osteoarthritis (OA) of the knee under its Phase 3 clinical trial of its lead drug candidate FX006.
FLXN: 21.29 (+0.28)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Flexion Therapeutics Initiates Phase 3 Clinical Trial of FX006 in Patients With Osteoarthritis of the Knee
GlobeNewswire - Mon Feb 02, 3:11PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced dosing of the first patient in the Phase 3 clinical trial of its lead drug candidate FX006 as a treatment for pain associated with osteoarthritis (OA) of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA or within the joint) formulation of triamcinolone acetonide (TCA). FX006 is designed for patients with moderate to severe OA pain and is intended to provide substantial and persistent pain relief while avoiding systemic side effects.
FLXN: 21.29 (+0.28)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), ANIK: 41.30 (-0.17), CBYL: ()
Increased Earnings Estimates Seen for Flexion Therapeutics (FLXN): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 7:44AM CST
Flexion Therapeutics has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well.
FLXN: 21.29 (+0.28)
Why Flexion Therapeutics (FLXN) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:46AM CST
One stock that might be an intriguing choice for investors right now is Flexion Therapeutics, Inc. (FLXN)in the Medical-Drug space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
FLXN: 21.29 (+0.28)
Will Flexion (FLXN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:44AM CST
Will Flexion (FLXN) Continue to Surge Higher?
FLXN: 21.29 (+0.28)
Why Flexion Therapeutics (FLXN) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:55AM CST
Flexion Therapeutics has seen a nice streak of beating earnings estimates especially when looking at the previous two reports. In fact, in these reports, FLXN has beaten estimates by at least 15% in both cases.
FLXN: 21.29 (+0.28)
Tinnitus - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/54b247/tinnitus) has announced the addition of the "Tinnitus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tinnitus and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Tinnitus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tinnitus and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tinnitus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tinnitus pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Merz Pharma GmbH & Co. KgaA - Auris Medical Holding AG - Knopp Biosciences LLC - Otonomy, Inc. - Sound Pharmaceuticals, Inc. - Synphora AB - Flexion Therapeutics, Inc. - Autifony Therapeutics Limited - AudioCure Pharma GmbH For more information visit http://www.researchandmarkets.com/research/54b247/tinnitus
FLXN: 21.29 (+0.28), EARS: 5.88 (-0.01), OTIC: 31.14 (+0.13)
InsiderInsights.com Daily Round Up 12/18/14: Agios Pharmaceuticals, Inc.,Unit Corporation, China Cord Blood Corporation, Saba Software, Inc.
InsiderInsights - at Seeking Alpha - Fri Dec 19, 9:49AM CST
FLXN: 21.29 (+0.28), NLSN: 45.59 (+2.02), HDP: 22.81 (+0.83), HDS: 28.62 (+0.24), PAH: 22.68 (+0.14), BURL: 51.91 (-0.56), SNI: 73.00 (+0.39), MFRM: 62.22 (-0.12), MPG: 18.90 (+0.73), UNT: 33.26 (+1.10), BFAM: 50.19 (+1.15), DYN: 28.39 (+0.01), AGIO: 118.55 (+0.11), WES: 71.50 (+0.18), CO: 4.75 (-0.06), KTEC: 12.53 (-0.02)
Flexion Therapeutics (FLXN) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:27AM CST
Flexion Therapeutics (FLXN) Shares March Higher, Can It Continue?
FLXN: 21.29 (+0.28)
Flexion Therapeutics concludes public offering of 5.796m common stock, including underwriters' over-allotment option
M2 - Thu Dec 18, 7:12AM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) revealed on Wednesday that it has completed its public offering of 5,796,000 shares of its common stock.
FLXN: 21.29 (+0.28)
Flexion Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of Public Offering of Common Stock
GlobeNewswire - Wed Dec 17, 8:35AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the closing of its previously announced underwritten public offering. A total of 5,796,000 shares of the Company's common stock were sold in the offering at a price to the public of $17.00 per share. The shares include 756,000 shares of common stock sold pursuant to the underwriters' over-allotment option, which option was exercised in full.
FLXN: 21.29 (+0.28)
Flexion Therapeutics (FLXN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:47AM CST
Flexion Therapeutics is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
FLXN: 21.29 (+0.28)
Flexion Therapeutics (FLXN) Worth Watching: Stock Up 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:25AM CST
Flexion Therapeutics (FLXN) was a big mover last session, with shares rising over 9% on the day.
LCI: 57.78 (-0.91), FLXN: 21.29 (+0.28), SCMP: 15.32 (+0.04), IG: 10.57 (-0.12)
Flexion Therapeutics prices public offering of 5.04m common shares
M2 - Mon Dec 15, 6:27AM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) said on Friday that it has priced its public offering of 5,040,000 shares of common stock.
FLXN: 21.29 (+0.28)
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Dec 12, 6:11AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of its underwritten public offering of 5,040,000 shares of common stock at a price to the public of $17.00 per share. Flexion has also granted the underwriters a 30-day option to purchase up to an additional 756,000 shares of common stock. The offering is expected to close on December 17, 2014, subject to customary closing conditions.
FLXN: 21.29 (+0.28)
Flexion Therapeutics to launch public offering of 3.5m common shares
M2 - Tue Dec 09, 6:44AM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) said on Monday that it intends to issue 3,500,000 shares of common stock in a public offering.
FLXN: 21.29 (+0.28)
3 Stocks Spiking on Big Volume: Baidu, LogMeIn and Flexion
at The Street - Fri Feb 13, 12:26PM CST
Keep these stocks rising on unusual volume on your trading radar.
FLXN: 21.29 (+0.28), BIDU: 212.13 (+7.11), LOGM: 52.22 (+4.17)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Flexion Therapeutics begins Phase 3 clinical trial of FX006 for osteoarthritis of the knee
M2 - Tue Feb 03, 8:26PM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) said on Monday that it has dosed the first patient with osteoarthritis (OA) of the knee under its Phase 3 clinical trial of its lead drug candidate FX006.
FLXN: 21.29 (+0.28)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Flexion Therapeutics Initiates Phase 3 Clinical Trial of FX006 in Patients With Osteoarthritis of the Knee
GlobeNewswire - Mon Feb 02, 3:11PM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced dosing of the first patient in the Phase 3 clinical trial of its lead drug candidate FX006 as a treatment for pain associated with osteoarthritis (OA) of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA or within the joint) formulation of triamcinolone acetonide (TCA). FX006 is designed for patients with moderate to severe OA pain and is intended to provide substantial and persistent pain relief while avoiding systemic side effects.
FLXN: 21.29 (+0.28)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), ANIK: 41.30 (-0.17), CBYL: ()
Increased Earnings Estimates Seen for Flexion Therapeutics (FLXN): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 7:44AM CST
Flexion Therapeutics has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well.
FLXN: 21.29 (+0.28)
Why Flexion Therapeutics (FLXN) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:46AM CST
One stock that might be an intriguing choice for investors right now is Flexion Therapeutics, Inc. (FLXN)in the Medical-Drug space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
FLXN: 21.29 (+0.28)
Will Flexion (FLXN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:44AM CST
Will Flexion (FLXN) Continue to Surge Higher?
FLXN: 21.29 (+0.28)
Why Flexion Therapeutics (FLXN) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:55AM CST
Flexion Therapeutics has seen a nice streak of beating earnings estimates especially when looking at the previous two reports. In fact, in these reports, FLXN has beaten estimates by at least 15% in both cases.
FLXN: 21.29 (+0.28)
Tinnitus - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/54b247/tinnitus) has announced the addition of the "Tinnitus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tinnitus and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Tinnitus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tinnitus and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tinnitus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tinnitus pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Merz Pharma GmbH & Co. KgaA - Auris Medical Holding AG - Knopp Biosciences LLC - Otonomy, Inc. - Sound Pharmaceuticals, Inc. - Synphora AB - Flexion Therapeutics, Inc. - Autifony Therapeutics Limited - AudioCure Pharma GmbH For more information visit http://www.researchandmarkets.com/research/54b247/tinnitus
FLXN: 21.29 (+0.28), EARS: 5.88 (-0.01), OTIC: 31.14 (+0.13)
InsiderInsights.com Daily Round Up 12/18/14: Agios Pharmaceuticals, Inc.,Unit Corporation, China Cord Blood Corporation, Saba Software, Inc.
InsiderInsights - at Seeking Alpha - Fri Dec 19, 9:49AM CST
FLXN: 21.29 (+0.28), NLSN: 45.59 (+2.02), HDP: 22.81 (+0.83), HDS: 28.62 (+0.24), PAH: 22.68 (+0.14), BURL: 51.91 (-0.56), SNI: 73.00 (+0.39), MFRM: 62.22 (-0.12), MPG: 18.90 (+0.73), UNT: 33.26 (+1.10), BFAM: 50.19 (+1.15), DYN: 28.39 (+0.01), AGIO: 118.55 (+0.11), WES: 71.50 (+0.18), CO: 4.75 (-0.06), KTEC: 12.53 (-0.02)
Flexion Therapeutics (FLXN) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:27AM CST
Flexion Therapeutics (FLXN) Shares March Higher, Can It Continue?
FLXN: 21.29 (+0.28)
Flexion Therapeutics concludes public offering of 5.796m common stock, including underwriters' over-allotment option
M2 - Thu Dec 18, 7:12AM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) revealed on Wednesday that it has completed its public offering of 5,796,000 shares of its common stock.
FLXN: 21.29 (+0.28)
Flexion Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of Public Offering of Common Stock
GlobeNewswire - Wed Dec 17, 8:35AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the closing of its previously announced underwritten public offering. A total of 5,796,000 shares of the Company's common stock were sold in the offering at a price to the public of $17.00 per share. The shares include 756,000 shares of common stock sold pursuant to the underwriters' over-allotment option, which option was exercised in full.
FLXN: 21.29 (+0.28)
Flexion Therapeutics (FLXN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:47AM CST
Flexion Therapeutics is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
FLXN: 21.29 (+0.28)
Flexion Therapeutics (FLXN) Worth Watching: Stock Up 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:25AM CST
Flexion Therapeutics (FLXN) was a big mover last session, with shares rising over 9% on the day.
LCI: 57.78 (-0.91), FLXN: 21.29 (+0.28), SCMP: 15.32 (+0.04), IG: 10.57 (-0.12)
Flexion Therapeutics prices public offering of 5.04m common shares
M2 - Mon Dec 15, 6:27AM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) said on Friday that it has priced its public offering of 5,040,000 shares of common stock.
FLXN: 21.29 (+0.28)
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Dec 12, 6:11AM CST
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of its underwritten public offering of 5,040,000 shares of common stock at a price to the public of $17.00 per share. Flexion has also granted the underwriters a 30-day option to purchase up to an additional 756,000 shares of common stock. The offering is expected to close on December 17, 2014, subject to customary closing conditions.
FLXN: 21.29 (+0.28)
Flexion Therapeutics to launch public offering of 3.5m common shares
M2 - Tue Dec 09, 6:44AM CST
Pharmaceutical company Flexion Therapeutics (NasdaqGM:FLXN) said on Monday that it intends to issue 3,500,000 shares of common stock in a public offering.
FLXN: 21.29 (+0.28)
